Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer chooses Exco InTouch eDiary technologies
Exco’s eDiary will allow patients to participate in the trial irrespective of their location, age or proximity to the site. The study, which will focus on new research
Exco’s eDiary will allow patients to participate in the trial irrespective of their location, age or proximity to the site. The study, which will focus on new research
The EU marketing authorization of BYDUREON is based on review of the submission package, including data from studies in the DURATION clinical program in which exenatide resulted in
The Phase 2 randomized, double-blind, placebo-controlled trial will recruit around 80 patinets. The study is designed to assess the efficacy, safety and tolerability of RP-G28 to treat the
Lonza said the new development and manufacturing services are available for both mammalian and microbial applications. Lonza is offering Light Path to customers from all five of its
Levofloxacin oral solution 25mg/mL is the generic for McNeil Pharmaceutical’s Levaquin oral solution. The solution is indicated for the treatment of adults with mild, moderate and severe infections.
Defibrotide is an investigational drug indicated to treat and prevent veno-occlusive disease (VOD). As part of the agreement, Medison will manage the named-patient sales program, local registration, authorization,
BAC’s CaptureSelect affinity purification and separation products are provided for the discovery, preclinical and clinical manufacturing of therapeutic proteins, including antibodies and antibody fragments. The collaboration creates a
Quotient Clinical’s RapidFACT service exploits its integrated GMP manufacturing and clinical testing processes and facilities to enable the clinical evaluation of new drug formulations. The company claims, compared
Besides being widely used in the production of pharmaceuticals, glycine is a component of infusion solutions and specialty nutrition items. The Germany-based company is investing in a new
Captisol technology was originally developed by Ligand’s subsidiary company CyDex Pharmaceuticals. The technology has enabled five FDA approved products, including Pfizer’s VFEND IV and Prism Pharmaceuticals’ NEXTERONE. Reportedly,